Chong Kun Dang Pharmaceutical Corp

Chong Kun Dang maintains a relatively strong liquidity position with a current ratio of 2.12, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which raises liquidity concerns. The debt-to-equity ratio of 0.37 suggests a moderate level of leverage, with long-term debt accounting for a significant portion of its liabilities. The company's profitability metrics are mixed. Return on equity (ROE) of 7.72% and return on assets (ROA) of 4.31% are below the typical thresholds for high-performing pharmaceutical firms. Gross profit of KRW 526.38 billion and operating income of KRW 80.55 billion indicate a solid gross margin, but the net income of KRW 77.51 billion suggests some pressure from operating expenses. Chong Kun Dang operates in a diversified product portfolio, including prescription drugs, OTC drugs, quasi-drugs, and health functional food. The company's revenue is primarily concentrated in domestic and overseas markets, though specific segment breakdowns are not disclosed. The lack of detailed geographic and segment revenue data limits the ability to assess exposure to specific regions or product lines. The company's growth trajectory is uncertain, as no specific revenue growth rates or outlooks are provided in the input data. However, the negative free cash flow of KRW -70.44 billion and capital expenditures of KRW -179.13 billion suggest significant reinvestment in the business, which could support long-term growth. Risk factors include a medium liquidity risk due to the negative net cash position and a moderate debt load. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the negative free cash flow and high capital expenditures may signal potential future dilution if the company needs to raise additional capital. Recent events and filings do not provide specific details on new product launches, regulatory changes, or strategic initiatives. Analysts have provided a mean price target of KRW 120,833.33 and a median price target of KRW 110,000.00, with a mean recommendation of 1.67, indicating a generally positive outlook.